Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (3173)	6/3/1999 9:06:00 AM
From: jeffbas	Read Replies (1) \| Respond to of 10280

For what it is worth, an opinion from a person not in the health field who does not own the stock: If it has been demonstrated that the isomer SEPR makes is the exclusive provider of the medical benefits, then I am appalled that they cannot claim benefits from not having to take the other isomer, without ANY further demonstrations. It ought to be FDA policy that it is a marketable advantage not to take unnecessary chemicals in order to achieve a desired effect. On the other hand, for management to get another letter is also appalling and a turnoff to buying the stock at any price. You always kiss the ass of the big kid on the block unless you want to get beat up. This is stupid.